During this study, 41 out of the 43 patients treated showed a positive response to treatment. Serenity has also completed an end-of-Phase-II meeting with the FDA.
John Sedor, president and CEO of Cpex, said: “In less than a year, our partner Serenity has taken this urology drug candidate from the investigational ew Drug application stage through an end-of-Phase-II meeting. Serenity’s continued commitment to rapid clinical development, in addition to the positive data collected in their clinical trials, make us optimistic as to the future potential of this drug candidate.
“In addition, this positive data, along with our ongoing progress with Nasulin, continue to validate the significant untapped potential of Cpex’s permeation enhancement technology. We look forward to providing more detail at a future date as its development continues.”